LivaNova PLC (LIVN)
NASDAQ: LIVN · Real-Time Price · USD
45.17
+0.82 (1.85%)
Jun 18, 2025, 4:00 PM - Market closed
LivaNova Employees
LivaNova had 2,900 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
2,900
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$439,786
Profits / Employee
-$76,602
Market Cap
2.46B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
LIVN News
- 14 days ago - CORE-VNS Study Further Validates Effectiveness of LivaNova's VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy - Business Wire
- 14 days ago - LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy - Business Wire
- 15 days ago - LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression - Business Wire
- 5 weeks ago - LivaNova to Present at the Jefferies Global Healthcare Conference - Business Wire
- 5 weeks ago - LivaNova PLC (LIVN) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance - Business Wire
- 6 weeks ago - LivaNova Announces 12-month Data from OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea, Demonstrating Strong Response and Durability of Therapy - Business Wire
- 3 months ago - LivaNova to Announce First-Quarter 2025 Results - Business Wire